IMMUNITYBIO, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IMMUNITYBIO, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $102.09M.
- IMMUNITYBIO, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $42.06M, a 221273.68% increase year-over-year.
- IMMUNITYBIO, INC. stock issued during period, value, new issues for the quarter ending 2021-06-30 was $94.89M, a 9.97% increase year-over-year.
- IMMUNITYBIO, INC. stock issued during period, value, new issues for the quarter ending 2020-12-31 was $0.00.
- IMMUNITYBIO, INC. stock issued during period, value, new issues for fiscal 2021 was $164.53M, a 90.64% increase from fiscal 2020.
- IMMUNITYBIO, INC. stock issued during period, value, new issues for fiscal 2020 was $86.30M, a 187.67% increase from fiscal 2019.
- IMMUNITYBIO, INC. stock issued during period, value, new issues for fiscal 2019 was $30.00M.
- IMMUNITYBIO, INC. stock issued during period, value, new issues for fiscal 2015 was $77.98M, a 36.00% increase from fiscal 2014.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $102.09M 10-Q · filed 2026-05-07 | |
| 2021-12-31 | $164.53M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $42.06M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $94.89M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $86.30M 10-K · filed 2023-03-01 |
| 2020-09-30 | $19.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $86.28M 10-Q · filed 2021-08-12 | |
| 2019-12-31 | $30.00M 10-K · filed 2022-03-01 | |
| 2015-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $77.98M 10-K · filed 2018-03-12 |
| 2015-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | |
| 2014-12-31 | $57.34M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |